Abstract
(N Engl J Med. 2022;387:109–119) Coronavirus disease 2019 (COVID-19) increases the risk of maternal and neonatal adverse outcomes. COVID-19 vaccines during pregnancy have been shown to be effective at mitigating the risks of severe COVID-19 side effects in the mother, yet infants <6 months of age are not eligible for the vaccination though still prone to adverse effects of the infection. COVID-19 vaccination of the mother during pregnancy may propagate vaccination benefits to the neonate through transplacental transfer of severe acute respiratory syndrome coronavirus 2 (SARs-CoV-2) antibodies and provide protection to infants. The aim of this study is to analyze maternal vaccination and the risk of hospitalization of infants younger than 6 months of age from COVID-19.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
